Is Mounjaro the Same as Ozempic? No, and Here's Exactly How They Differ

Key Takeaways

• Mounjaro and Ozempic are different drugs. Mounjaro contains tirzepatide; Ozempic contains semaglutide. The active ingredients are different molecules made by different manufacturers.
• Mounjaro is a dual GLP-1 and GIP receptor agonist. Ozempic acts on GLP-1 receptors only. The dual mechanism produces larger weight-loss and A1C-lowering effects in head-to-head trials.
• Both are FDA-approved for type 2 diabetes. Mounjaro is made by Eli Lilly; Ozempic is made by Novo Nordisk. Their weight-loss-approved siblings are Zepbound (tirzepatide) and Wegovy (semaglutide).
• In the SURPASS-2 head-to-head trial, tirzepatide produced larger A1C reductions (about 2.0 to 2.3 points vs 1.9 points for semaglutide 1 mg) and larger weight loss (about 7.6 kg to 11.2 kg vs 5.7 kg).
• Side effect profiles overlap heavily. Both cause nausea, diarrhea, constipation, and reduced appetite. Tirzepatide's GI symptoms are slightly more common at higher doses but rates of treatment discontinuation are similar between drugs.

Direct answer (40-60 words)

No, Mounjaro and Ozempic are not the same. Mounjaro is tirzepatide, a dual GLP-1/GIP receptor agonist made by Eli Lilly. Ozempic is semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. Both treat type 2 diabetes, but in head-to-head trials tirzepatide produced larger A1C reductions and more weight loss than semaglutide.

Table of contents

1. The 30-second answer
2. Active ingredients: tirzepatide vs semaglutide
3. Mechanism of action side by side
4. FDA approvals and indications
5. Head-to-head clinical trial data
6. Dosing and titration schedules
7. Side effects compared
8. Cost and insurance coverage compared
9. Storage, injection, and pen design
10. How to choose between them with your provider
11. FAQ

Active ingredients: tirzepatide vs semaglutide

The single biggest difference is that Mounjaro and Ozempic contain different active drugs.

Mounjaro is the brand name for tirzepatide, a 39-amino-acid peptide engineered by Eli Lilly. Tirzepatide is structurally based on the GIP (glucose-dependent insulinotropic polypeptide) sequence with modifications that allow it to also bind the GLP-1 receptor. It received FDA approval for type 2 diabetes in May 2022.

Ozempic is the brand name for semaglutide, a 31-amino-acid peptide developed by Novo Nordisk. Semaglutide is a modified form of the natural GLP-1 hormone with a fatty-acid side chain (C18 diacid) that extends its half-life to about 7 days. It received FDA approval for type 2 diabetes in December 2017.

Both are weekly subcutaneous injections. Both improve blood glucose. Both promote weight loss. But they're chemically distinct molecules with different binding profiles, different efficacy data, and different patent holders.

Mechanism of action side by side

The mechanism difference is the most important reason the two drugs perform differently in trials.

Ozempic (semaglutide) acts on GLP-1 receptors only. GLP-1 (glucagon-like peptide-1) is a gut hormone released after meals. When semaglutide binds GLP-1 receptors, it:

• Stimulates glucose-dependent insulin secretion from pancreatic beta cells
• Suppresses glucagon release from alpha cells
• Slows gastric emptying
• Reduces appetite via central nervous system effects on the hypothalamus and brainstem

Mounjaro (tirzepatide) acts on both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is a separate gut hormone with overlapping but distinct effects. By activating both receptors, tirzepatide produces:

• Stronger insulin secretion (additive GLP-1 and GIP effects)
• Possibly enhanced lipid metabolism via GIP-mediated effects on adipose tissue
• Effects on energy expenditure that may contribute to greater weight loss
• Larger gastric emptying delay than GLP-1 alone

The dual mechanism is what differentiates the SURPASS and SURMOUNT trial results from the SUSTAIN and STEP trial results. (See section 5.)

FDA approvals and indications

Mounjaro and Ozempic are both labeled for type 2 diabetes. Their weight-management equivalents (Zepbound and Wegovy) are FDA-approved separately at higher dose schedules. The active ingredient is the same as the diabetes-approved version, but the brand name and labeled indication differ.

When patients ask "is Mounjaro the same as Ozempic for weight loss," the answer involves both the molecule difference (tirzepatide vs semaglutide) and the indication difference (off-label diabetes drugs vs labeled weight-loss drugs).

Head-to-head clinical trial data

The SURPASS-2 trial directly compared tirzepatide and semaglutide in patients with type 2 diabetes. This is the only large-scale head-to-head study of these two drugs.

SURPASS-2 (Frias et al., NEJM 2021), N = 1,879:

Tirzepatide at all three doses produced larger A1C reductions than semaglutide 1 mg, and weight loss was approximately 1.9 kg to 5.5 kg greater on tirzepatide depending on dose.

For obesity-only populations (without diabetes), the most relevant comparison is between SURMOUNT-1 (tirzepatide for obesity, Jastreboff et al., NEJM 2022) and STEP 1 (semaglutide 2.4 mg for obesity, Wilding et al., NEJM 2021):

• SURMOUNT-1: mean weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks
• STEP 1: mean weight loss of 14.9% on semaglutide 2.4 mg over 68 weeks

These are different trials with different populations, so direct percentage comparison is imperfect, but the consistent signal across studies is that tirzepatide produces somewhat greater weight loss than semaglutide at maximum doses.

The SURMOUNT-5 head-to-head trial of tirzepatide vs semaglutide in obesity (results published 2025) confirmed this, with tirzepatide producing a 20.2% mean weight loss vs 13.7% for semaglutide.

Dosing and titration schedules

Both drugs require gradual dose escalation to minimize GI side effects.

Mounjaro titration schedule:

• Weeks 1 to 4: 2.5 mg weekly
• Weeks 5 to 8: 5 mg weekly
• Optional: 7.5 mg, 10 mg, 12.5 mg, 15 mg (escalate every 4 weeks if tolerated)
• Maximum: 15 mg weekly

Ozempic titration schedule:

• Weeks 1 to 4: 0.25 mg weekly
• Weeks 5 to 8: 0.5 mg weekly
• Optional: 1 mg weekly after at least 4 weeks at 0.5 mg
• Maximum: 2 mg weekly

The two drugs are not dose-equivalent. 1 mg of semaglutide is not "the same as" 5 mg or 10 mg of tirzepatide. Each drug has its own dose range based on the receptor binding affinity and pharmacokinetics of the molecule.

Switching between them requires a provider-directed transition. There is no standard "1 mg semaglutide equals X mg tirzepatide" conversion. Most clinicians restart titration from the lower starting dose when switching.

Side effects compared

Side effect profiles are similar but not identical.

(Source: SURPASS-2, SURMOUNT-1, SUSTAIN-7, STEP 1 published trial data.)

Both drugs share the same boxed warning: risk of thyroid C-cell tumors based on rodent studies. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Both share the same other warnings: pancreatitis, gallbladder disease, hypoglycemia (when combined with insulin or sulfonylureas), acute kidney injury, diabetic retinopathy complications (semaglutide more studied), and hypersensitivity reactions.

A 2024 meta-analysis (Karagiannis et al., Diabetologia 2024) of GLP-1 vs GLP-1/GIP head-to-head trials found that tirzepatide had marginally higher rates of nausea and vomiting than semaglutide at peak titration doses, but discontinuation rates were comparable.

Cost and insurance coverage compared

Insurance coverage:

• Both Mounjaro and Ozempic are covered by most commercial plans for type 2 diabetes with prior authorization.
• Both are typically not covered for weight-loss-only indications under Medicare (statutory exclusion).
• The weight-loss-approved siblings (Zepbound, Wegovy) have separate prior-authorization criteria.

A 2024 KFF analysis estimated average net cost (after manufacturer rebates and savings cards) at $87 monthly for commercially insured type 2 diabetes patients across both Mounjaro and Ozempic.

Storage, injection, and pen design

The Mounjaro single-dose pen is simpler to use (no dialing) but generates more medical waste than the multi-dose Ozempic pen. The Ozempic multi-dose pen requires patients to track which dose they're on each week.

Both pens use 32G needles in standard prescribing. Both are subcutaneous injections in the abdomen, thigh, or upper arm.

How to choose between them with your provider

The choice between Mounjaro and Ozempic depends on five factors most often:

1. Indication. For type 2 diabetes, both are FDA-approved. For weight loss specifically, the FDA-approved options are Zepbound (tirzepatide) and Wegovy (semaglutide), not Mounjaro or Ozempic.
2. Insurance coverage. Your plan's formulary may prefer one over the other. Prior authorization criteria can differ.
3. Tolerance to GI side effects. Both drugs cause nausea, but tirzepatide patients in head-to-head data had marginally higher rates at peak doses. If you've tried one and tolerated it poorly, switching to the other may or may not help.
4. Weight-loss goals. If maximum weight loss is the priority, tirzepatide produces somewhat greater results in head-to-head data. If A1C lowering is the focus, both are highly effective.
5. Cardiovascular risk profile. Semaglutide has a larger cardiovascular outcomes evidence base (SUSTAIN-6, SELECT). Tirzepatide's CV outcomes trial (SURPASS-CVOT) reported in 2024 with comparable findings.

Talk to your prescribing provider about which fits your medical history, insurance, and goals. Self-selection between brand-name GLP-1 medications is not appropriate. (See our guide to getting started on GLP-1 therapy for the typical evaluation process.)

FAQ

Is Mounjaro the same as Ozempic? No. Mounjaro contains tirzepatide; Ozempic contains semaglutide. They're different molecules with different mechanisms (dual GLP-1/GIP for Mounjaro vs GLP-1 only for Ozempic) and different efficacy profiles in clinical trials.

Can I switch from Ozempic to Mounjaro? Yes, with provider supervision. There is no direct dose conversion. Most clinicians restart titration from the Mounjaro 2.5 mg starting dose, with re-escalation every 4 weeks if tolerated. Switching is typically done because of insurance changes, side effect issues, or efficacy goals.

Is Mounjaro stronger than Ozempic? For A1C reduction and weight loss, head-to-head data (SURPASS-2, SURMOUNT-5) shows tirzepatide produces somewhat larger effects than semaglutide at maximum doses. "Stronger" is appropriate shorthand for these endpoints. Both drugs are highly effective.

Are the side effects of Mounjaro and Ozempic the same? Mostly yes. Both cause nausea, diarrhea, vomiting, constipation, and reduced appetite. Tirzepatide has slightly higher rates of GI side effects at peak doses, but treatment discontinuation rates are similar.

Can I take both Mounjaro and Ozempic at the same time? No. Combining two GLP-1 receptor agonists is not approved and risks additive adverse effects without proportional benefit. Patients should be on one or the other, never both.

Why do some patients lose more weight on Mounjaro? Tirzepatide's dual GLP-1/GIP mechanism produces larger weight loss in trials than GLP-1 alone. The GIP component contributes to additional appetite reduction and possibly metabolic effects. Individual response varies; some patients lose more on semaglutide.

Is Zepbound the same as Mounjaro? Zepbound and Mounjaro both contain tirzepatide. They have the same active ingredient, made by the same manufacturer (Eli Lilly), but are FDA-approved for different indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes.

Is Wegovy the same as Ozempic? Both contain semaglutide and are made by Novo Nordisk. They have FDA approval for different indications: Ozempic for type 2 diabetes, Wegovy for chronic weight management. Wegovy is dosed higher (2.4 mg max) than Ozempic (2 mg max).

Are Mounjaro and Ozempic interchangeable? No. They're different drugs and not pharmacologically interchangeable. Pharmacy substitution requires a new prescription. Insurance plans treat them as separate formulary items.

Which is cheaper, Mounjaro or Ozempic? List prices are similar, with Ozempic slightly lower. Manufacturer savings cards bring eligible commercially insured patients to as low as $25 monthly on either drug. Cash prices vary by pharmacy.

Is the boxed warning the same on both drugs? Yes. Both Mounjaro and Ozempic carry the same boxed warning about thyroid C-cell tumors based on rodent studies, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN-2.

Can I get Mounjaro or Ozempic through telehealth? Yes, through legitimate telehealth platforms with U.S.-licensed providers and pharmacy partners. The provider performs an evaluation, writes a prescription, and routes it to a U.S.-licensed pharmacy. Both brand-name medications are available this way.

Sources (numbered list)

1. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
4. Aronne LJ, et al. Tirzepatide vs semaglutide in obesity (SURMOUNT-5). N Engl J Med. 2025.
5. Marso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
6. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
7. Eli Lilly. Mounjaro and Zepbound Prescribing Information, 2026 update.
8. Novo Nordisk. Ozempic, Wegovy, and Rybelsus Prescribing Information, 2026 update.
9. Karagiannis T, et al. Comparative efficacy of GLP-1 and dual GIP/GLP-1 receptor agonists. Diabetologia. 2024.
10. Sorli C, et al. Efficacy and safety of once-weekly semaglutide (SUSTAIN-7). Lancet Diabetes Endocrinol. 2017;5:251-260.
11. American Diabetes Association. Standards of Care in Diabetes 2026, Pharmacologic approaches to glycemic treatment.
12. Kaiser Family Foundation. GLP-1 spending and coverage analysis. KFF Health News, 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by either company.